Benzinga | Aug 19, 2021 05:01AM EDT

Jefferies Initiates Coverage On Apellis Pharmaceuticals with Buy Rating, Announces Price Target of $74

Jefferies analyst Chris Howerton initiates coverage on Apellis Pharmaceuticals (NASDAQ:APLS) with a Buy rating and announces Price Target of $74.